SURGICAL ONCOLOGY

PAPER – I

SURGONCO/J/17/47/I

Time : 3 hours Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

| 1. | | What are the factors contributing to cancer associated thrombosis? Prophylaxis and management of thrombosis in a surgical patient. | 4+(3+3) |
|-----|----|--|---------|
| 2. | b) | What is "sequencing"? What is Next Generation Sequencing? Impact of Next Generation Sequencing in oncology. | 3+3+4 |
| 3. | | Meta-analysis. Impact factor. | 6+4 |
| 4. | b) | What is standard fractionation? What are the altered fractionation techniques available? Advantages and disadvantages of hyperfractionation. | 2+3+5 |
| 5. | | What is Minimally Invasive Surgery (MIS)? Impact of MIS on outcomes in oncology. | 3+7 |
| 6. | | Treatment of neuropathic pain. Long acting opioids. | 5+5 |
| 7. | b) | Name the different phases of cell cycle. Explain role of cyclin dependent kinases. Regulation of cell cycle. | 2+4+4 |
| 8. | | Advantages of a cohort study. Median survival. | 6+4 |
| 9. | | What is prophylactic surgery in oncology? Indications, techniques and current status of contra-lateral prophylactic mastectomy. | 6+4 |
| 10. | | Classify platinum compounds. Their mechanisms of action, indications and their toxicity. | 3+7 |